M
Michael Palmer
Researcher at National Institutes of Health
Publications - 23
Citations - 5440
Michael Palmer is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Letrozole & Breast cancer. The author has an hindex of 19, co-authored 23 publications receiving 5069 citations. Previous affiliations of Michael Palmer include Keele University & McMaster University.
Papers
More filters
Journal ArticleDOI
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Paul E. Goss,James N. Ingle,Silvana Martino,Nicholas J. Robert,Hyman B. Muss,Martine Piccart,Monica Castiglione,Dongsheng Tu,Lois E. Shepherd,Kathleen I. Pritchard,Robert B. Livingston,Nancy E. Davidson,Larry Norton,Edith A. Perez,Jeffrey S. Abrams,Patrick Therasse,Michael Palmer,Joseph L. Pater +17 more
TL;DR: As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.
Journal ArticleDOI
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
Paul E. Goss,James N. Ingle,Silvana Martino,Nicholas J. Robert,Hyman B. Muss,Martine Piccart,Monica Castiglione,Dongsheng Tu,Lois E. Shepherd,Kathleen I. Pritchard,Robert B. Livingston,Nancy E. Davidson,Larry Norton,Edith A. Perez,Jeffrey S. Abrams,David Cameron,Michael Palmer,Joseph L. Pater +17 more
TL;DR: Letrozole after tamoxifen is well-tolerated and improves both disease- free and distant disease-free survival but not overall survival, except in node-positive patients.
Journal ArticleDOI
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
Paul E. Goss,James N. Ingle,Silvana Martino,Nicholas J. Robert,Hyman B. Muss,Martine Piccart,Monica Castiglione,Dongsheng Tu,Lois E. Shepherd,Kathleen I. Pritchard,Robert B. Livingston,Nancy E. Davidson,Larry Norton,Edith A. Perez,Jeffrey S. Abrams,Patrick Therasse,Michael Palmer,Joseph L. Pater +17 more
TL;DR: As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.
Journal ArticleDOI
Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
James Chih-Hsin Yang,Vera Hirsh,Martin Schuler,Nobuyuki Yamamoto,Kenneth J. O'Byrne,Tony Mok,Victoria Zazulina,Mehdi Shahidi,Juliane Lungershausen,Dan Massey,Michael Palmer,Lecia V. Sequist +11 more
TL;DR: In this paper, a randomized, phase III trial of Afatinib or cisplatin/pemetrexed was conducted to investigate patient-reported symptoms and health-related quality of life (QoL) benefits.
Journal ArticleDOI
Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women
Timothy J. Whelan,Paul E. Goss,James N. Ingle,Joseph L. Pater,Dongsheng Tu,Kathleen I. Pritchard,Shifang Liu,Lois E. Shepherd,Michael Palmer,Nicholas J. Robert,Silvana Martino,Hyman B. Muss +11 more
TL;DR: Letrozole did not have an adverse impact on overall QOL and small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis.